Morgan Stanley Upgrades Jazz Pharmaceuticals (JAZZ) to Overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Morgan Stanley Upgrades Jazz Pharmaceuticals (JAZZ) to Overweight

Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Truist Securities

December 16, 2024 4:54 AM EST

Truist Securities analyst Gregory Fraser raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $220.00 (from $200.00) while maintaining a Buy rating.

The analyst comments "We see underlying growth potential in JAZZ's Ziihera (zanidatamab) franchise driven by derisked indications. With Ziihera now... More